Kornitzer Capital Management’s NovoCure NVCR Stock Holding History

Kornitzer Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-174,035	Closed	-$19.4M	–	495
2020 Q3	$19.4M	Sell	174,035 -898	-0.5%	-$71.8K	0.38%	79
2020 Q2	$10.4M	Buy	174,933 +81,193	+87%	+$5.34M	0.21%	164
2020 Q1	$6.31M	Buy	93,740 +43,390	+86%	+$3.43M	0.15%	193
2019 Q4	$4.24M	Sell	50,350 -3,500	-6%	-$283K	0.07%	270
2019 Q3	$4.03M	Buy	+53,850	New	+$4.31M	0.07%	274
2018 Q4	–	Sell	-225,600	Closed	-$11.8M	–	488
2018 Q3	$11.8M	Buy	225,600 +510	+0.2%	+$20.3K	0.19%	163
2018 Q2	$7.04M	Buy	+225,090	New	+$6.26M	0.12%	211

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Kornitzer Capital Management's NVCR Position: Q4 2020 in Review

Kornitzer Capital Management sold out of NovoCure (NVCR) in Q4 2020, closing a stake of 174,035 shares — an estimated $19.4M sold.

Kornitzer Capital Management first reported a position in NVCR in Q2 2018 and held it in 7 quarters. The position peaked at $19.4M in Q3 2020. 356 funds tracked by Wall St. Rank hold NVCR as of Q4 2020.

Kornitzer Capital Management reported no remaining NovoCure position as of Q4 2020 after selling out during the quarter.
Kornitzer Capital Management sold 174,035 NovoCure shares in Q4 2020, an estimated $19.4M.
Kornitzer Capital Management first reported a position in NovoCure in Q2 2018 and held it in 7 quarters.
Kornitzer Capital Management's NovoCure position peaked at $19.4M in Q3 2020.
356 funds tracked by Wall St. Rank held NovoCure as of Q4 2020.

Based on Kornitzer Capital Management's 13F filing for Q4 2020, filed 29 Jan 2021.